Turning Point in the Treatment of Mantle Cell Lymphoma

被引：1

作者：

Motokura, Toru ^{[1
]}

机构：

[1] Tottori Univ, Fac Med, Sch Med, Div Clin Lab Med,Dept Pathophysiol & Therapeut Sc, Yonago, Tottori 6838503, Japan

来源：

YONAGO ACTA MEDICA | 2019年 / 62卷 / 01期

关键词：

bendamustine; bortezomib; ibrutinib; lymphoma; mantle-cell; BRUTON TYROSINE KINASE; PROGNOSTIC INDEX MIPI; 15-YEAR FOLLOW-UP; OPEN-LABEL; B-CELL; PROLYMPHOCYTIC LEUKEMIA; 1ST-LINE TREATMENT; DOSE CYTARABINE; P53; MUTATIONS; PHASE-II;

D O I：

10.33160/yam.2019.03.001

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Mantle cell lymphoma (MCL) is an incurable type of B-cell lymphoma. It is typically composed of small-to-medium-sized cleaved lymphoid cells with cyclin D1 protein expression due to the chromosomal translocation t(11;14)(q13;q32). Even with the development of rituximab, an anti-CD20 antibody drug, the long-term outcome of patients with MCL has not improved. Recently, new agents have been used in clinical settings, and the outcome of patients with MCL is expected to improve. The treatment of MCL may be at a turning point from intensive chemotherapy to chemotherapy-free treatment. In this study, a recent progress in the diagnosis and treatment of MCL is reviewed.

引用

页码：1 / 7

页数：7

共 49 条

[1] A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma [J].

Armand, Philippe ;

Redd, Robert ;

Bsat, Jad ;

Mayuram, Sangeetha ;

Giardino, Angela ;

Fisher, David C. ;

LaCasce, Ann S. ;

Jacobson, Caron ;

Davids, Matthew S. ;

Brown, Jennifer R. ;

Weng, Li ;

Wilkins, Jennifer ;

Faham, Malek ;

Freedman, Arnold S. ;

Joyce, Robin ;

Jacobsen, Eric D. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (01) :89-95

[2] MANTLE CELL LYMPHOMA - A PROPOSAL FOR UNIFICATION OF MORPHOLOGICAL, IMMUNOLOGICAL, AND MOLECULAR-DATA [J].

BANKS, PM ;

CHAN, J ;

CLEARY, ML ;

DELSOL, G ;

DEWOLFPEETERS, C ;

GATTER, K ;

GROGAN, TM ;

HARRIS, NL ;

ISAACSON, PG ;

JAFFE, ES ;

MASON, D ;

PILERI, S ;

RALFKIAER, E ;

STEIN, H ;

WARNKE, RA .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (07) :637-640

[3]

Chan WC, 1997, BLOOD, V89, P3909

[4] Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients [J].

Chang, Betty Y. ;

Francesco, Michelle ;

De Rooij, Martin F. M. ;

Magadala, Padmaja ;

Steggerda, Susanne M. ;

Huang, Min Mei ;

Kuil, Annemieke ;

Herman, Sarah E. M. ;

Chang, Stella ;

Pals, Steven T. ;

Wilson, Wyndham ;

Wiestner, Adrian ;

Spaargaren, Marcel ;

Buggy, Joseph J. ;

Elias, Laurence .

BLOOD, 2013, 122 (14) :2412-2424

[5] VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study [J].

Chang, Julie E. ;

Carmichael, Lakeesha L. ;

Kim, KyungMann ;

Peterson, Christopher ;

Yang, David T. ;

Traynor, Anne M. ;

Werndli, Jae E. ;

Huie, Michael S. ;

McFarland, Thomas A. ;

Volk, Michael ;

Blank, Jules ;

Callander, Natalie S. ;

Longo, Walter L. ;

Kahl, Brad S. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) :E61-E67

[6] RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106 [J].

Chen, Robert W. ;

Li, Hongli ;

Bernstein, Steven H. ;

Kahwash, Samir ;

Rimsza, Lisa M. ;

Forman, Stephen J. ;

Constine, Louis ;

Shea, Thomas C. ;

Cashen, Amanda F. ;

Blum, Kristie A. ;

Fenske, Timothy S. ;

Barr, Paul M. ;

Phillips, Tycel ;

Leblanc, Michael ;

Fisher, Richard I. ;

Cheson, Bruce D. ;

Smith, Sonali M. ;

Faham, Malek ;

Wilkins, Jennifer ;

Leonard, John P. ;

Kahl, Brad S. ;

Friedberg, Jonathan W. .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (05) :759-769

[7] Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center [J].

Chihara, Dai ;

Cheah, Chan Y. ;

Westin, Jason R. ;

Fayad, Luis E. ;

Rodriguez, Maria A. ;

Hagemeister, Fredrick B. ;

Pro, Barbara ;

McLaughlin, Peter ;

Younes, Anas ;

Samaniego, Felipe ;

Goy, Andre ;

Cabanillas, Fernando ;

Kantarjian, Hagop ;

Kwak, Larry W. ;

Wang, Michael L. ;

Romaguera, Jorge E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (01) :80-88

[8] Differences in incidence and trends of haematological malignancies in Japan and the United States [J].

Chihara, Dai ;

Ito, Hidemi ;

Matsuda, Tomohiro ;

Shibata, Akiko ;

Katsumi, Akira ;

Nakamura, Shigeo ;

Tomotaka, Sobue ;

Morton, Lindsay M. ;

Weisenburger, Dennis D. ;

Matsuo, Keitaro .

BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (04) :536-545

[9] p53 mutations and tetraploids under r- and K-selection [J].

Chikatsu, N ;

Nakamura, Y ;

Sato, H ;

Fujita, T ;

Asano, S ;

Motokura, T .

ONCOGENE, 2002, 21 (19) :3043-3049

[10] Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis [J].

Cinar, Munevver ;

Hamedani, FaridSaei ;

Mo, Zhicheng ;

Cinar, Bekir ;

Amin, Hesham M. ;

Alkan, Serhan .

LEUKEMIA RESEARCH, 2013, 37 (10) :1271-1277

← 1 2 3 4 5 →